重组人血小板生成素治疗肿瘤化疗后血小板减少的临床观察

目的评价重组人血小板生成素（rhTPO）治疗肿瘤化疗后血小板减少的疗效和安全性。方法 2008年12月2009年10月收住恶性肿瘤患者45例,在化疗后出现血小板减少,随机分为A、B组,A组皮下注射rhTPO（15000U/d）,B组皮下注射白细胞介素-11（1.5mg/d）,动态监测注射后血小板生长情况。结果 A组血小板计数的最低值明显高于B组（P〈0.05）;A组血小板开始恢复时间较B组明显缩短（P〈0.01）;血小板恢复至100×109/L以上所需时间A组较B组明显缩短（P〈0.05）,分别为（6.18±4.20）和（10.46±4.54）d,血小板恢复的最高值两组差异无统计学意义（P〉0.05）;B组有2例患者化疗后需要输入外源性血小板,A组无患者需要输入血小板;与B组比较,A组较少发生不良反应,患者可以耐受。结论重组人血小板生成素是一种治疗化疗后出现血小板减少的有效方法。

Clinical Observation on Recombinant Human Thrombopoietin Treating Chemotherapy-induced Thrombocytopenia

Objective To evaluate the therapeutic effect of recombinant human thrombopoietin（rhTPO）on chemotherapy-induced thrombocytopenia.Methods Forty-five in-patients with malignant tumor from December 2008 to October 2009who had thrombocytopenia after chemotherapy were randomly divided into A and B groups.The pa-tients in group A underwent the hypodermic injection with rhTPO（15 000U/d）while in group B with interleukin-11 （1.5mg/d）;the platelet count was checked consecutively.Results Compared with that in group B,the platelet count was obviously higher（P0.01）and the time of declined platelet count beginning to recover was significantly shorter in group A.The time of platelet count increasing to 100×109/L was within（6.18±4.20）days in group B which was significantly shorter than（10.46±4.54）days in group B（P0.05）.However,no significant was found between the two groups in the maximal platelet count（P0.05）.Two patients needed platelet transfusion in group B and no one did in group A.Conclusion rhTPO is safe and effective for chemotherapy-induced thrombocytopenia.